MannKind gets out the ax (again) as Afrezza sales fizzle; Bristol-Myers gains new Opdivo/Yervoy approval at the FDA;

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

> With sales of Afrezza barely registering at Sanofi, MannKind ($MNKD) has triggered its third round of layoffs, with the ax falling throughout its organization. MannKind's shares dropped to a 52-week low--around the $3 mark--as the news spread. Story

> Bristol-Myers Squibb ($BMY) won FDA approval for a combination of Opdivo and Yervoy to treat metastatic melanoma. Release

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Intarcia buys Phoundry in search of additional diabetes drugs for its subdermal drug pump. Story | Follow @FierceMedDev

@VarunSaxena2: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: New Hampshire AG launches investigation into opioid marketing. Article | Follow @EmilyWFierce

> Neuravi ready to take on Medtronic, Stryker in burgeoning market for devices to fight stroke. More

Pharma News

@FiercePharma: Sun Pharmaceutical's Shanghvi drops from top spot in Forbes India rich list. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Merck KGaA counts on Latin America to power consumer-health future. Article | Follow @CarlyHFierce

> Express Scripts: Strict prior-auth moves keep a tight lid on PCSK9 sales. Story

> Novartis stacks up more data for lucrative Cosentyx expansion. Article

Vaccines News

> Novavax's RSV jab protects infants in PhII, nets $89M Gates Foundation grant. Article

> Advaxis targets HER2 cancers with first-in-human vaccine trial. Story

> BiondVax, EU's UNISEC team up for universal flu jab PhIIb. More

> PRA Health joins with clinical research network to improve vaccine studies. Item

> NewLink wins $26.1M in government funding to advance Ebola vaccine. Report

CRO News

> Frontage doubles its bioanalytics space. Item

> Accelovance snags another Big Pharma cancer vet to boost its onco profile. Report

> PRA partners up to accelerate vaccine R&D. More

> Patheon rebrands with a $100M IPO in the works. Story

> Chiltern expands in diabetes after a big buyout. Article

Pharma Manufacturing News

> Siegfried completes $302M deal for BASF API plants. News

> EPA presents Pfizer with $194M bill to cleanup former American Cyanide site. Report

> Abbott said to expand manufacturing, other operations in India. Story

> Will a desktop device that synthesizes lidocaine revolutionize pharma manufacturing? More

> Hovione set to expand its NJ facility and add new spray dryer. Article

Pharma Asia News

> China slaps Fosun Pharma unit with small fine for anti-monopoly violations. News

> Singapore's Biosensors launches sales of BMX-J stent in key Japan market. More

> Australia's Paranta Biosciences raises A$7M for PhI of cystic fibrosis candidate. Report

> China biotech CARsgen inks deal with Shanghai Cancer Institute on candidate focus. Story

> MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. Article

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.